DK2864473T3 - Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus - Google Patents

Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus Download PDF

Info

Publication number
DK2864473T3
DK2864473T3 DK13733516.2T DK13733516T DK2864473T3 DK 2864473 T3 DK2864473 T3 DK 2864473T3 DK 13733516 T DK13733516 T DK 13733516T DK 2864473 T3 DK2864473 T3 DK 2864473T3
Authority
DK
Denmark
Prior art keywords
insulin
treatment
diabetes mellitus
cells
dependent diabetes
Prior art date
Application number
DK13733516.2T
Other languages
Danish (da)
English (en)
Inventor
William L Rust
Original Assignee
Seraxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seraxis Inc filed Critical Seraxis Inc
Application granted granted Critical
Publication of DK2864473T3 publication Critical patent/DK2864473T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DK13733516.2T 2012-06-26 2013-06-24 Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus DK2864473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261664259P 2012-06-26 2012-06-26
PCT/US2013/047243 WO2014004341A1 (en) 2012-06-26 2013-06-24 Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
DK2864473T3 true DK2864473T3 (da) 2019-09-23

Family

ID=48746139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13733516.2T DK2864473T3 (da) 2012-06-26 2013-06-24 Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus

Country Status (16)

Country Link
US (2) US9968639B2 (https=)
EP (2) EP2864473B1 (https=)
JP (2) JP6386453B2 (https=)
KR (2) KR102174581B1 (https=)
CN (2) CN113265370A (https=)
AU (2) AU2013280698B2 (https=)
BR (1) BR112014031676A2 (https=)
CA (1) CA2876677C (https=)
DK (1) DK2864473T3 (https=)
EA (2) EA201992135A1 (https=)
ES (1) ES2745704T3 (https=)
IL (2) IL236346B (https=)
IN (1) IN2015DN00281A (https=)
PT (1) PT2864473T (https=)
SG (1) SG11201408717XA (https=)
WO (1) WO2014004341A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467918B (zh) * 2015-08-18 2020-07-31 中国科学技术大学先进技术研究院 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用
CN105434471A (zh) * 2015-11-26 2016-03-30 深圳爱生再生医学科技有限公司 治疗糖尿病的干细胞制剂及其制备方法
EP3749752A1 (en) * 2018-02-09 2020-12-16 Seraxis, Inc. Pancreatic cells for treating diabetes and methods of generating the same
KR20210077698A (ko) * 2018-10-15 2021-06-25 사이니티 가부시키가이샤 저분자 화합물에 의한 내배엽 조직 또는 기관 유래 세포로부터의 줄기/전구 세포의 제작 방법
WO2021117840A1 (ja) * 2019-12-11 2021-06-17 国立大学法人 東京大学 Ｍｙｃｌの一過性発現による増殖可能な膵島前駆細胞様細胞の誘導とインスリン陽性細胞への分化誘導
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
US20230330264A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
JP2026505821A (ja) 2023-02-03 2026-02-18 セラクシス，インコーポレーテッド 治療細胞およびそれらに関連する方法
WO2025029826A1 (en) 2023-07-31 2025-02-06 Seraxis, Inc. Modified therapeutics cells and methods relating to the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861313A (en) * 1995-06-07 1999-01-19 Ontogeny, Inc. Method of isolating bile duct progenitor cells
AU2376200A (en) 1999-01-07 2000-07-24 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
AU2003268534A1 (en) 2002-09-06 2004-03-29 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
CA2527626A1 (en) 2003-06-20 2004-12-29 Vrije Universiteit Brussel Method of generating islet beta-cells from exocrine pancreatic cells
CA2581424A1 (en) * 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
US20060029987A1 (en) 2004-08-06 2006-02-09 Applera Corporation Diagnosis of pancreatic cancer by using pancreatic targets
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
US20100137202A1 (en) * 2006-07-19 2010-06-03 University Of Florida Research Foundation Compositions for reprogramming a cell and uses therefor
WO2008112278A2 (en) 2007-03-12 2008-09-18 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
CA2692634C (en) 2007-11-09 2014-05-27 Rnl Bio Co., Ltd Method for isolating and culturing adult stem cells derived from human amniotic epithelium
WO2009128533A1 (ja) 2008-04-18 2009-10-22 国立大学法人名古屋大学 間葉系幹細胞およびその生産方法
CN102083964B (zh) * 2008-05-09 2013-06-12 格拉斯哥大学大学行政评议会 与基于细胞的疗法相关的材料和方法
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
JP2012513218A (ja) * 2008-12-23 2012-06-14 ヴィヴォスクリプト，インコーポレイテッド 遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
WO2011032025A2 (en) * 2009-09-10 2011-03-17 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
SG187830A1 (en) * 2010-08-22 2013-03-28 Univ Ramot Induced pluripotent stem cells derived from human pancreatic beta cells
EP2611907B1 (en) * 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CN103210082A (zh) * 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
WO2012044486A1 (en) * 2010-09-28 2012-04-05 Baylor Research Institute Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdxi selection

Also Published As

Publication number Publication date
US20150231181A1 (en) 2015-08-20
JP6856586B2 (ja) 2021-04-07
KR20190141263A (ko) 2019-12-23
CN104640979B (zh) 2021-05-04
KR102058259B1 (ko) 2019-12-23
ES2745704T3 (es) 2020-03-03
AU2013280698A1 (en) 2015-01-22
WO2014004341A1 (en) 2014-01-03
EP3611255A1 (en) 2020-02-19
JP6386453B2 (ja) 2018-09-05
IL236346A0 (en) 2015-02-26
JP2015522281A (ja) 2015-08-06
CA2876677C (en) 2021-09-07
IL266965B (en) 2021-08-31
PT2864473T (pt) 2019-09-27
KR102174581B1 (ko) 2020-11-06
EP2864473B1 (en) 2019-08-21
EP2864473A1 (en) 2015-04-29
KR20150036059A (ko) 2015-04-07
BR112014031676A2 (pt) 2017-10-31
JP2018193394A (ja) 2018-12-06
CN104640979A (zh) 2015-05-20
US20130344594A1 (en) 2013-12-26
AU2019202085A1 (en) 2019-04-18
EA033954B1 (ru) 2019-12-13
EA201590088A1 (ru) 2015-04-30
EA201992135A1 (ru) 2020-02-05
AU2013280698B2 (en) 2019-01-17
US9968639B2 (en) 2018-05-15
CN113265370A (zh) 2021-08-17
CA2876677A1 (en) 2014-01-03
US9474772B2 (en) 2016-10-25
IL236346B (en) 2019-06-30
SG11201408717XA (en) 2015-02-27
IN2015DN00281A (https=) 2015-06-12
IL266965A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
DK2864473T3 (da) Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus
DK2555807T5 (da) Skabelon-øceller og små øcelleklynger til behandling af diabetes
DK2858496T3 (da) Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
DK3347027T3 (da) Neo-øer omfattende stam- og øceller og behandling af diabetes mellitus dermed
DK2658965T3 (da) Fremgangsmåde til fremstilling af inducerede pluripotente stamceller og differentierede celler
HRP20160862T1 (hr) Sklop posude i pridruženi postupak
DK2567690T3 (da) Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK2765966T3 (da) System, interfaceanordninger, anvendelse af interfaceanordningerne og fremgangsmåde til øjenkirurgi
DK3495380T3 (da) Glucagon/glp-1-coagonister til behandling af obesitas
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
DK3260140T3 (da) Fremgangsmåder og produkter til transficering af celler
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK2699553T3 (da) Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK2839004T3 (da) Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation
DK2970890T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
DK4082530T3 (da) Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3357830T3 (da) Beholderlukning og fremgangsmåde til fremstilling af samme
DK2893001T3 (da) Fremgangsmåde til dyrkning af mesenkymale stamceller
DK2861273T3 (da) Anvendelse af heparin og kulhydrater til behandling af cancer.
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri